Freshfields LLP is a leading British multinational law firm headquartered in London, England, and a member of the Magic Circle of elite UK law firms. Founded with origins tracing back to 1743, it expanded significantly in 2000 through mergers with German firms Deringer Tessin Herrmann & Sedemund and Bruckhaus Westrick Heller Löber, operating until 2024 as Freshfields Bruckhaus Deringer before rebranding to its current legal name.
The firm employs over 4,900 people, including 427 partners and 1,611 associates, across 28 offices in 17 jurisdictions worldwide, spanning Europe, Asia, the Middle East, and North America. Its practice areas encompass banking and finance, capital markets, corporate/M&A, antitrust, international arbitration, litigation, private equity, projects, energy, real estate, and tax.
Freshfields advises multinational corporations, financial institutions, and governments. It maintains a dedicated chemicals practice, serving many of the world's top 100 chemicals companies with expertise in M&A, joint ventures, regulatory compliance (including REACH and PFAS), project financing, antitrust, and litigation. Notable transactions include advising Saint-Gobain on acquisitions of Fosroc and GCP Applied Technologies, LANXESS on its purchase from IFF, and Borealis on a divestiture to Agrofert.
Also known as FRESHFIELDS BRUCKHAUS DERINGER LLP.
None yet. When a new project in the record names Freshfields as owner, partner or investor, it shows here.
FB102 shows Phase 1b proof in vitiligo and celiac; Phase 2 in celiac expected H2 2026. Acquisition executed as $77/share cash tender offer; close targeted Q3 2026.
Board (excluding Nassef and Nadia Sawiris) backs NNS cash offer and court-appointed directors agree to convene an EGM to approve the Orascom transaction, conditional on NNS declaring and settling the offer.
Adds full NPK fertilizer technologies, fluorine and oleochemistry capabilities; integrates ~460 staff, pilot plants and a €270m backlog; transaction paid at €148.2m.
Azeglio-based Gomet sold to Trelleborg for €42.5m; 2025 revenue ~€24m; proceeds to reduce outstanding borrowings.
Acquirer to buy target biotech at $53/share (~$6.7B equity, ~$5.7B net). Lead oral allosteric BCR::ABL1 TKI showed week‑24 molecular responses in Phase1/2; expected Q2 2026.
